164 related articles for article (PubMed ID: 28718307)
21. Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy.
Silva NN; Eng C
J Adv Pract Oncol; 2012 May; 3(3):161-9. PubMed ID: 25031942
[TBL] [Abstract][Full Text] [Related]
22. Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation.
Knitter JR; Erly WK; Stea BD; Lemole GM; Germano IM; Doshi AH; Nael K
AJR Am J Roentgenol; 2018 Jul; 211(1):168-175. PubMed ID: 29708785
[TBL] [Abstract][Full Text] [Related]
23. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.
Zikou A; Sioka C; Alexiou GA; Fotopoulos A; Voulgaris S; Argyropoulou MI
Contrast Media Mol Imaging; 2018; 2018():6828396. PubMed ID: 30627060
[TBL] [Abstract][Full Text] [Related]
24. Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?
Shah AH; Snelling B; Bregy A; Patel PR; Tememe D; Bhatia R; Sklar E; Komotar RJ
J Neurooncol; 2013 Apr; 112(2):141-52. PubMed ID: 23344789
[TBL] [Abstract][Full Text] [Related]
25. Distinguishing pseudoprogression from progression in high-grade gliomas: a brief review of current clinical practice and demonstration of the potential value of 18F-FDG PET.
Oborski MJ; Laymon CM; Lieberman FS; Mountz JM
Clin Nucl Med; 2013 May; 38(5):381-4. PubMed ID: 23510887
[TBL] [Abstract][Full Text] [Related]
26. Pseudoprogression of low-grade gliomas after radiotherapy.
Naftel RP; Pollack IF; Zuccoli G; Deutsch M; Jakacki RI
Pediatr Blood Cancer; 2015 Jan; 62(1):35-9. PubMed ID: 25213668
[TBL] [Abstract][Full Text] [Related]
27. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas.
Ma B; Blakeley JO; Hong X; Zhang H; Jiang S; Blair L; Zhang Y; Heo HY; Zhang M; van Zijl PC; Zhou J
J Magn Reson Imaging; 2016 Aug; 44(2):456-62. PubMed ID: 26788865
[TBL] [Abstract][Full Text] [Related]
28. Sequential proton boost after standard chemoradiation for high-grade glioma.
Adeberg S; Bernhardt D; Harrabi SB; Uhl M; Paul A; Bougatf N; Verma V; Unterberg A; Wick W; Haberer T; Combs SE; Herfarth K; Debus J; Rieken S
Radiother Oncol; 2017 Nov; 125(2):266-272. PubMed ID: 29050959
[TBL] [Abstract][Full Text] [Related]
29. Late Pseudoprogression: A Potential Pitfall in 68Ga-DOTATATE PET/CT for Glioma.
Li L; Tian Y; He Y
Clin Nucl Med; 2023 Apr; 48(4):e207-e208. PubMed ID: 36728314
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of amino acid PET in assessing treatment response to temozolomide in glioma.
Prather KY; O'Neal CM; Westrup AM; Tullos HJ; Hughes KL; Conner AK; Glenn CA; Battiste JD
Neurooncol Adv; 2022; 4(1):vdac008. PubMed ID: 35300149
[TBL] [Abstract][Full Text] [Related]
31. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
[TBL] [Abstract][Full Text] [Related]
32. Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3-4) Gliomas.
Flies CM; van Leuken KH; Ten Voorde M; Verhoeff JJC; De Vos FYF; Seute T; Robe PA; Witkamp TD; Hendrikse J; Dankbaar JW; Snijders TJ
Neurology; 2022 Jul; 99(1):e77-e88. PubMed ID: 35437259
[TBL] [Abstract][Full Text] [Related]
33. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Prager AJ; Martinez N; Beal K; Omuro A; Zhang Z; Young RJ
AJNR Am J Neuroradiol; 2015 May; 36(5):877-85. PubMed ID: 25593202
[TBL] [Abstract][Full Text] [Related]
34. Initial results of a phase II trial of
Breen WG; Youland RS; Giri S; Jacobson SB; Pafundi DH; Brown PD; Hunt CH; Mahajan A; Ruff MW; Kizilbash SH; Uhm JH; Routman DM; Jones JE; Brinkmann DH; Laack NN
J Neurooncol; 2022 Jul; 158(3):323-330. PubMed ID: 35583721
[TBL] [Abstract][Full Text] [Related]
35. 18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma.
Bogsrud TV; Londalen A; Brandal P; Leske H; Panagopoulos I; Borghammer P; Bach-Gansmo T
Clin Nucl Med; 2019 Aug; 44(8):605-611. PubMed ID: 31274605
[TBL] [Abstract][Full Text] [Related]
36. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
37. Letter to the Editor: Depression As The First Symptom Of Frontal Lobe Grade 2 Malignant Glioma.
Nazlı ŞB; Sevindik M
Turk Psikiyatri Derg; 2022; 33(2):143-145. PubMed ID: 35730515
[TBL] [Abstract][Full Text] [Related]
38. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
[TBL] [Abstract][Full Text] [Related]
39.
Deuschl C; Kirchner J; Poeppel TD; Schaarschmidt B; Kebir S; El Hindy N; Hense J; Quick HH; Glas M; Herrmann K; Umutlu L; Moenninghoff C; Radbruch A; Forsting M; Schlamann M
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):593-601. PubMed ID: 29282517
[TBL] [Abstract][Full Text] [Related]
40. Pseudoprogression of brain tumors.
Thust SC; van den Bent MJ; Smits M
J Magn Reson Imaging; 2018 May; 48(3):571-89. PubMed ID: 29734497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
